
This medication is compounded by a licensed 503A pharmacy in accordance with Section 503A of the Federal Food, Drug & Cosmetic Act, and may only be dispensed pursuant to a valid, patient-specific prescription issued by a licensed healthcare practitioner following an individualized medical evaluation. The FDA does not review or approve compounded medications, including compounded tirzepatide, for safety, effectiveness, or quality. Compounded tirzepatide has not been FDA-approved for weight loss or any other indication, though peer-reviewed and third-party research suggests potential clinical benefits. Individual results will vary. This compounded formulation is not affiliated with, endorsed by, reviewed by, or intended to replace any FDA-approved product manufactured by Eli Lilly and Company. EOS Health and its pharmacy partners have no affiliation with Eli Lilly and Company.
Compounded Tirzepatide is a once-weekly injectable that acts on two hormone pathways involved in appetite and digestion — GLP-1 and GIP — rather than one. It is prescribed for weight management when a U.S.-licensed clinician determines it is appropriate.
Two-hormone mechanism: Tirzepatide acts on both the GLP-1 and GIP receptors, the pathways involved in satiety signaling and gastric emptying.
Appetite and fullness: Acts on the signals that regulate hunger and how long you feel full after eating.
Once-weekly dosing: One subcutaneous injection per week, with dosing set and adjusted by your clinician.
Blood sugar regulation: Influences insulin and glucagon signaling as part of how the medication acts on metabolism.
Clinician-managed titration: Your dose starts low and changes only under provider guidance, which is how side effects are managed.